AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT05986526 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Pulmonary vein isolation without posterior wall ablation
Description: Pulmonary vein isolation with Pulsed field ablation without left atrial posterior wall ablation. At the end of the procedure, an implantable cardiac monitor will be implanted for the purpose of continuous arrhythmia monitoring
Study NCT05986526 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Pulmonary vein isolation with posterior wall ablation
Description: Pulmonary vein isolation with Pulsed field ablation with left atrial posterior wall ablation. At the end of the procedure, an implantable cardiac monitor will be implanted for the purpose of continuous arrhythmia monitoring
Study NCT04558814 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Serum galectin-9 level
Description: Determining level of galectin-9 in sera of patients of SLE with different disease activity and organ affection and Sera of control group
Study NCT06221475 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BAY2927088 coated tablet 10 mg
Description: 4 coated tablets (10 mg) per single dose 30 min after a light meal
Study NCT06221475 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [14C]-BAY2927088 solution for infusion
Description: IV infusion 15 min ending at 2 hours oral post-dose
Study NCT06221475 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [14C]-BAY2927088 oral solution
Description: After a light meal
Study NCT05915442 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Quemliclustat
Description: 100mg IV once every two weeks
Study NCT05915442 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etrumadenant
Description: 150 mg orally (PO) once a day (QD)
Study NCT05915442 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zimberelimab
Description: 240 mg IV once every two weeks starting within 1 week of completing metastasis-directed SBRT
Study NCT05915442 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Stereotactic Body Radiation Therapy
Description: Standard of care metastasis-directed hypofractionated radiotherapy treatment starting 4 weeks (+/- 1 week) of starting Etrumadenant and Quemliclustat
Study NCT04940910 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Black rice bran extract
Description: 2 times a day, 2 capsule for 1 time, after breakfast/dinner meal, for 8 week
Study NCT04940910 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 2 times a day, 2 capsule for 1 time, after breakfast/dinner meal, for 8 week
Study NCT05190003 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Experimental Study
Description: On the basis of neurosurgical examination and MRI imaging, 40 patients aged 20-65 years with pains in the lumbar spine will be referred for the first-time single-level microdiscectomy procedure. Microdiscectomy patients will begin a rehabilitation program that will be includes exercises to reduce pain and strengthen the stabilizing muscles of the lumbar spine. From week to week, exercises will be difficult, among others due to the change of initial positions, the number of repetitions of exercises, or a longer duration of isometric exercises.
Study NCT05143073 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Alcohol use disorder and strategies to reduce risk educational material
Description: Participants will be directed to educational information (\~5 minutes) regarding alcohol use disorder and strategies to reduce risk which they will read.
Study NCT05143073 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Complex polygenic risk scores, alcohol use disorder, and strategies to reduce risk educational material
Description: Participants will be directed to educational information (\~10 minutes) regarding complex polygenic risk scores, alcohol use disorder and strategies to reduce risk which they will read.
Study NCT05692037 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Selective internal radiation therapy (SIRT) with yttrium-90 carbon microspheres
Description: Yttrium-90 carbon microspheres SIRT
Study NCT05393466 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BPI-361175
Description: BPI-361175 is an oral fourth-generation EGFR inhibitor. The activation of EGFR signaling pathways is associated with various biological events such as proliferation, migration, differentiation, and apoptosis.
Study NCT05472727 — intervention group
Intervention type: OTHER
Intervention: reaction time test
Description: Reaction time tests consist of 3 sub-parameters as simple reaction time, selective reaction time and distinctive reaction time. Participants will do these tests on the computer.
Study NCT05472727 — intervention group
Intervention type: OTHER
Intervention: Physical fitness test
Description: The physical fitness test will be evaluated with the senior fitness test used for geriatrics and the 8 meter walking speed test.
Study NCT05688943 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Spinal Anesthesia
Description: Fentanyl (1µg/kg) and midazolam are administered intravenously prior to puncture. Using an aseptic technique, the subarachnoid space is punctured with a 25/27 gauge needle in the intervertebral space, and a standard dose of chloroprocaine 45-60mg is injected. Alternative spinal anesthetics include bupivacaine 6-15mg and mepivacaine 50-70mg. The participant is then placed in the supine position in 10-degree Trendelenburg until the lack of sensitivity is adequate at spinal level T4.
Study NCT05688943 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: General Anesthesia
Description: General anesthesia is a state of controlled unconsciousness. During a general anesthetic, medicines are used to send the participant to sleep making the participant unaware of surgery and so that the participant does not move or feel pain while the surgery is carried out. Induction of general anesthesia includes the use intravenous sedative-hypnotic agents such as propofol, etomidate, or ketamine, along with adjuvant agents such as fentanyl, lidocaine, or midazolam. A neuromuscular blocking agent such as succinylcholine or rocuronium is used to facilitate endotracheal intubation.
Study NCT05797701 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SAR443820
Description: Tablet by oral administration
Study NCT05797701 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SAR443820
Description: Capsule by oral administration
Study NCT05167942 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: deep transcranial magnetic stimulation with H1 coil
Description: Sham deep transcranial magnetic stimulation on PFC .Duration:40 days.
Study NCT05167942 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: High frequency deep transcranial magnetic stimulation with H1 coil
Description: high frequency(20Hz) deep transcranial magnetic stimulation on PFC .Duration:40 days.
Study NCT05167942 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: iTBS deep transcranial magnetic stimulation with H1 coil
Description: iTBS deep transcranial magnetic stimulation on PFC .Duration:40 days.
Study NCT04879043 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HDP-101
Description: HDP-101 is available as lyophilized white powder for preparation of infusion.
Study NCT05446545 — intervention group
Intervention type: OTHER
Intervention: ND-EOC or platinum-sensitive rEOC
Description: platinum-based combined chemotherapy or bevacizumab will be used for adjuvant treatment, followed by maintenance therapy with poly adenosine diphosphate-ribose polymerase (PARP) inhibitor, or bevacizumab, or other anti-tumor angiogenesis drugs or immune checkpoint inhibitors
Study NCT05680363 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: HyperSperm
Description: Multi-step sperm preparation
Study NCT05680363 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Standard Sperm Preparation
Description: Standard sperm preparation
Study NCT05479500 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Myofascial Chain Release Techniques
Description: Myofascial release is a hands on technique which stretches the fascia and releases, bonds between muscles, integuments and fascia in order to eliminate pain, improve motion and to maintain myofascial balance within the body.
Study NCT05479500 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Local Release Techniques
Description: Local Release Techniques are a soft tissue method that focuses on relieving tissue tension via the removal of fibrosis/adhesions which can develop in tissues as a result of overload due to repetitive use.
Study NCT06374823 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Multiple Electrolyte
Description: Patients who are randomized to multiple electrolyte group will be receiving Multiple Electrolytes injection II for 72 hours continously after inrollment as maintence and rescutation fluids. Infusion speed and volume will be determained by physicians.
Study NCT06374823 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Normal Saline
Description: Patients who are randomized to normal saline group will be receiving Sodium Chloride injection for 72 hours continously after inrollment as maintence and rescutation fluids. Infusion speed and volume will be determained by physicians.
Study NCT05235035 — intervention group
Intervention type: BEHAVIORAL
Intervention: Night shift work
Description: Subjects are exposed to irregular sleep and sleep misalignment due to hospital night shifts.
Study NCT06518122 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HCP1306
Description: Take it once a day per period.
Study NCT06518122 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RLD2302
Description: Take it once a day per period.
Study NCT06518122 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RLD2102
Description: Take it once a day per period
Study NCT04887493 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Misoprostol
Description: Misoprostol 25µg will be used for both the study arms
Study NCT06290050 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Midazolam
Description: Midazolam syrup.
Study NCT06290050 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Repaglinide
Description: Repaglinide tablets.
Study NCT06290050 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAK-279
Description: TAK-279 capsules.
Study NCT06136546 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Infliximab
Description: Intravenous infusion of infliximab
Study NCT06136546 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Intravenous infusion of saline solution (matching in color and consistency in infliximab)
Study NCT06037330 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nalbuphine
Description: Nalbuphine was injected intravenously. The target CPOT score was \<2, and the target RASS score was -2 \~ 1. 40 mg of nalbuphine was diluted into 50 mL solution, the load was 0.1mg/kg, the maintenance dose was 0.04-0.08mg/kg/h, the CPOT score was \<2, and the maximum daily dose was 160mg.
Study NCT06037330 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sufentanil
Description: Sufentanil was injected intravenously, and the target CPOT score was \<2, and the target RASS score was -2 \~ 1. 0.1mg of sufentanil was diluted into 50 mL solution, the loading dose was 0.2-0.5μg/kg, the maintenance dose was 0.2-0.3μg/kg/h, and the CPOT score was \<2 points
Study NCT06087354 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: The way of Cumulus-oocyte complexes (COC) CAPA-IVM culture condition
Description: Cumulus-oocyte complexes (COC) will be cultured in CAPA-IVM 24 hrs capacitation followed by 30h maturation. The first group will be cultured in low oxygen concentration (5%Oxygen), 6% carbon dioxide at 37 degree. The second group will be cultured in air oxygen concentration (20%Oxygen), 6% carbon dioxide at 37 degree.
Study NCT04791046 — intervention group
Intervention type: DRUG
Intervention: antihypertensive therapy
Description: Personalized evidence-based antihypertensive therapy in patients with comorbidities
Study NCT06240884 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Infraspinatus-teres minor interfascial block
Description: After identifying the infraspinatus and teres minor muscles on the posterior surface of the scapular neck. Under real-time ultrasound guidance, the needle is advanced into the interfascial plane between the infraspinatus and teres minor muscles using an in-plane technique, and after confirming the fascial opening with 3 to 5 mL of 0.375% ropivacaine (20 mL total dose), the remaining 0.375% ropivacaine is injected. After extubation and the patients were awake, anesthesiologists who were unaware of the study subgroups began to assess the analgesic effect of the patients' block at rest using the numeric pain rating scale (NRS) at 0.5h, 3h, 6h, 12h, 18h, 24h, and 48h postoperatively.
Study NCT06240884 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: interscalene block
Description: The tip of the needle was placed between the C5 and C6 nerve roots, and after a bloodless retraction with 0.5 to 1 ml of 0.375% ropivacaine to confirm nerve displacement, the remaining 0.375% ropivacaine was injected (total dose of 20 ml). Subsequently, the catheter was inserted over the needle and the needle was withdrawn.After extubation and the patients were awake, anesthesiologists who were unaware of the study subgroups began to assess the analgesic effect of the patients' block at rest using the numeric pain rating scale (NRS) at 0.5h, 3h, 6h, 12h, 18h, 24h, and 48h postoperatively.
Study NCT06329037 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vasopressin
Description: Administration of Vasopressin (20 IU) (oral spray)
Study NCT06329037 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Administration of Placebo (oral spray)
Study NCT05567237 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Microcurrent treatment with resistance exercise programme
Description: This intervention will allow us to explore the effects of microcurrent added to resistance exercise.
Study NCT05567237 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Resistance exercise programme
Description: This intervention works as a control group for the participants undergoing the exercise programme.
Study NCT05567237 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Microcurrent treatment
Description: This intervention will allow us to explore the effects of microcurrent alone.
Study NCT05567237 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: No treatment
Description: This intervention works as a control group for the participants who are not taking part into the exercise programme.
Study NCT04943991 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: blood sampling (alpha-Galactosidase & LysoGb3)
Description: A blood sample will be taken. Alpha-Galactosidase level and LysoGb3 will be measured.~Amendment: Offering of genetic testing for fabry specific GLA-gene
Study NCT05138835 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Botox Cosmetic
Description: BOTOX® Cosmetic is approved and commercially available for use in Canada.~BOTOX® Cosmetic is a prescription medicine that is injected into muscles and used to temporarily improve the look of moderate to severe frown lines between the eyebrows, crow's feet lines, and forehead lines in adults.
Study NCT05138835 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Botox Cosmetic
Description: BOTOX® Cosmetic is approved and commercially available for use in Canada.~BOTOX® Cosmetic is a prescription medicine that is injected into muscles and used to temporarily improve the look of moderate to severe frown lines between the eyebrows, crow's feet lines, and forehead lines in adults.
Study NCT06569992 — intervention group
Intervention type: OTHER
Intervention: VIS, TIES
Description: The vasopressor and inotropic drug dosages administered during the follow-up of these patients will be recorded, and the Vasoactive-Inotropic Score (VIS) and Total Inotrope Exposure Score (TIES) will be calculated.
Study NCT06092073 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: recto-intercostal fascial plane block
Description: Patients will receive bilateral recto-intercostal fascial plane block using 20 mL of bupivacaine 0.25% on each side.
Study NCT06092073 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: bupivacaine
Description: bupivacaine 0.25%
Study NCT05583266 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pentoxifylline sustained-release tablets
Description: a dose of 1 tablet twice a day of Pentoxifylline sustained-release tablets
Study NCT05583266 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Pentoxifylline sustained-release tablets placebo
Description: Pentoxifylline sustained-release tablets placebo will be administrated at the same dosage and frequency as the experimental group
Study NCT05149690 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Experimental: monopolar dielectric diathermy and supervised therapeutic exercise
Description: The Experimental Group formed by 30 subjects will undergo an application of monopolar electrical diathermy by radiofrequency emission (MDR) using the Physicalm® device developed by the electro-medicine company Biotronic Advance Develops SL, on the lumbar musculature by means of rotary movements and translation, adapting to the muscle fibers of the lumbar area. A pulsed emission of 840 KHz and 30v will be made dynamically during a treatment time of 20 minutes. Once the application of (MDR) is finished, an exercise program supervised by a physiotherapist will be carried out. The exercise program will consist mainly of three types: stability and lumbo-pelvic motor control, strengthening and stretching of the lumbar muscles (Annex XIV), with a duration of 20 minutes. 2 weekly sessions will be held for 4 weeks, distributed as follows: Monday and Wednesday or Tuesday and Thursday, a total of 8 treatment sessions.
Study NCT05149690 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Active Comparator: Supervised therapeutic exercise
Description: The Control Group formed by 30 subjects will be administered a training program consisting of three types of exercises, taking into account: stability and lumbopelvic motor control, strengthening and stretching of the lumbar muscles, exactly the same as the Experimental Group. With a duration of 20 minutes. 2 weekly sessions will be held for 4 weeks, distributed as follows: Monday and Wednesday or Tuesday and Thursday with a total of 8 treatment sessions.
Study NCT06130267 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Endocare
Description: Virtual paradigm (calming environnement)
Study NCT06130267 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Endocare
Description: Virtual paradigm (calming environnement)
Study NCT04652271 — intervention group
Intervention type: PROCEDURE
Intervention: Pancreatic surgery
Description: Open, laparoscopic or robotic surgery of the pancreas
Study NCT04864730 — intervention group
Intervention type: OTHER
Intervention: No intervention
Description: No intervention
Study NCT05672342 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cannabidiol
Description: Given PO
Study NCT05672342 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Delta-8-Tetrahydrocannabinol
Description: Given PO
Study NCT05672342 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Administration
Description: Given PO
Study NCT05672342 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies
Study NCT05672342 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Questionnaire Administration
Description: Ancillary studies
Study NCT05686174 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: MBS217
Description: Soybean Fermented Extract (MBS217)
Study NCT05686174 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Without active ingredient
Study NCT04760665 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Fecal microbiota transplantation
Description: Patients will receive four fecal microbiota transplantation (FMT) capsules. Microbiota is obtained from healthy patients.
Study NCT04760665 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Patients will receive four oral capsules containing placebo. These capsules will have the same shape, weight and colour as capsules containing FMT.
Study NCT06407310 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: I.V Pembrolizumab (keytruda) 200 mg every 3 weeks for 6 cycles
Study NCT06407310 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: I.V Carboplatin at AUC 1.5 weekly for a total of 12 weeks.
Study NCT06407310 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: I.V Paclitaxel at 80 mg/m2 weekly for a total of 12 weeks.
Study NCT05407259 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Resistance exercise
Description: There will be four conditions (three exercises and one control) on visits 3-6. For the three exercise conditions, all training parameters except intensity will be the same. The sets in high, moderate, and low intensity correspond to the rate of perceived exertion (0-10 scale) 7-9, 5-6, and 3-4, respectively. Therefore, the participants will perform 5 repetitions barbell squat, barbell press, and barbell deadlift with 8RM (78% 1RM), 11RM (72% 1RM), and 16RM (65% 1RM) for 3 sets
Study NCT05331014 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LivaloVA
Description: For 8 weeks(PO, QD)